

Inmedix® raises \$250,000 over 10 years to support the Pediatric Rheumatology Division at Seattle Children's

Its 10th Annual Golf event adds \$43,695.44 to support kids with autoimmune joint diseases.

NORMANDY PARK, WA, UNITED STATES, October 6, 2026 /EINPresswire.com/ -- Seattle-based biotech/medtech [Inmedix®](#), Inc. continued to support kids with arthritis and autoimmune disease at its 10th annual Inmedix



charity golf tournament at the Club at Snoqualmie Ridge on Monday, August 31, 2026. Today, it announced a final tally of \$43,695.44 raised. After ten annual events, the company has provided just over \$250,000 in support of research and other pressing needs within the Pediatric Rheumatology Division at Seattle Children's.

To ensure that all collected fees go 100% to support kids with arthritis, every entry check is made out to "Seattle Children's". After golf and the awards banquet, the comprehensive bill is given to the event's sole sponsor, Inmedix Inc.

Since FDA-clearance of CloudHRV® in January 2025, Inmedix has begun to provide its diagnostic to clinicians to quantify autonomic nervous system (ANS) biology. CloudHRV is the first system cleared by the FDA as a cloud-based, heart rate variability (HRV) diagnostic calculated from a high-fidelity 5-min electrocardiogram (ECG) which also includes Baevsky indices of parasympathetic and sympathetic activity. It represents a milestone in modern HRV assessment with validation, scalability, precision and affordability for patients and their caregivers in the clinical setting.

"Eight years before Inmedix revenue and the commercial launch of FDA-cleared Inmedix CloudHRV for the clinic, the company decided to lead a charity golf event to support kids with autoimmune disease and arthritis at Seattle Children's," said Andrew J. Holman, MD, local rheumatologist, Inmedix CEO and Co-founder, and Clinical Professor of Medicine at the University of Washington. "Now, just over \$250,000 has been raised from 10 annual events to support the fantastic team at Seattle Children's pediatric rheumatology. Of all of the milestones

reached by Inmedix, supporting this project has been so very important to us.”

The 11th annual Inmedix Charity Golf event is planned for late August 2027. Thank you to so many wonderful and generous patrons participating year after year, the Club at Snoqualmie Ridge, its catering, groundskeepers and pro shop staff, and to the folks at BackSwing Golf Events for making these annual affairs so successful.

About Inmedix, Inc. and its subsidiary, Inmedix UK, Ltd.

Seattle-based biotech/medtech Inmedix, Inc. and its subsidiary Inmedix UK, Ltd., are committed to engaging in world class research to discover innovative solutions for pressing healthcare needs related to the impact of stress, modulated within the brain by the autonomic nervous system (ANS). The Inmedix® CloudHRV® diagnostic system is leading the development of medical grade heart rate variability (HRV) for the clinic.

NOTICE:

This press release contains certain forward-looking statements, including without limitation statements regarding Inmedix’s plans for preclinical studies and product capabilities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Inmedix’s business which could significantly affect expected results, including without limitation, progress of development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Inmedix undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. This is not an offer to sell or an offer to purchase securities.

Andrew Holman
Inmedix Inc.
+12064663349 ext.
andrew.holman@inmedix.com
Visit us on social media:
[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/947570097>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.